Thanks to rndtbl over on IV for posting this article "Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What’s Old Is New Again."

https://www.ncbi.nlm.nih.gov/pubmed/30590974

Also, rndtbl provided link to this study from 2017 "Do BRD(4)S of a feather flock together? How an inflammation driven epigenetic regulator may link pulmonary hypertension and coronary artery disease."

https://www.ncbi.nlm.nih.gov/pubmed/28747456

The above references the 2017 study by Meloche J. et al "Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension."

https://www.ncbi.nlm.nih.gov/pubmed/28473439

For more info on the Resverlogix/Apabetalone clinical program for PAH, here is an Agoracom post from five months ago: New Apabetalone Clinical Trial for Pulmonary Arterial Hypertension with some good links.

Just one final note. Although the current ClinicalTrials.gov listing indicates start date of February 2019, the latest Resverlogix Corporate Update from January 2019 provides guidance of H2 2019 start for this trial.

BearDownAZ

P.S. Thanks for the great posts rndtbl!